Suven Life to present positive pharmacology data of 4 NCEs at SFN 2013

08 Nov 2013 Evaluate

Suven Life Sciences will be presenting positive pharmacology data of 4 advanced molecules from their portfolio of investigational neuroscience new chemical entities (NCEs) at SFN 2013 to be held at San Diego, USA during November 9-14, 2013. Key pharmacology, ADME and Safety data on selected NCEs, SUVN-G3031 (Histamine-3 receptor antagonist), SUVN-911 (Nicotinic acetylcholine alpha-4-beta-2 receptor antagonist), SUVN-D4010 (5-HT4 receptor partial agonist), SUVN-512 (5HT6 antagonists), CB2 agonist and M! modulators to treat the unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer’s, Schizophrenia, ADHD; Depression & Mood Disorders and Neuropathic Pain would be presented by Suven scientists at SFN-2013.

During SFN-2013 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore integrated collaborative research programs (CRP) and also Drug Discovery and Development Support Services (DDDSS) in addition to continued discussions with global Pharma majors regarding their clinical candidate SUVN-502.

Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro-Scientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating at this conference.

Suven Life Sciences Share Price

131.75 -3.65 (-2.70%)
23-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1814.50
Dr. Reddys Lab 1340.80
Cipla 1476.45
Lupin 2160.20
Zydus Lifesciences 972.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.